RVRC (Revium Recovery) Asset Impairment Charge : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2009. Start your Free Trial

What is Revium Recovery Asset Impairment Charge?

Revium Recovery's Asset Impairment Charge for the six months ended in . 20 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Revium Recovery Asset Impairment Charge Historical Data

The historical data trend for Revium Recovery's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revium Recovery Asset Impairment Charge Chart

Revium Recovery Annual Data

Trend

Asset Impairment Charge

Revium Recovery Semi-Annual Data

Asset Impairment Charge

Revium Recovery Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Asset Impairment Charge for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Revium Recovery Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Revium Recovery's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Revium Recovery Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Revium Recovery Inc (OTCPK:RVRC) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 HaMenofim Street, Herzliya, ISR, 4672561

Website

https://www.reviumrecovery.com

Revium Recovery Inc is focused on the development of a disruptive, methodical, and novel proprietary Clinical Decision Support software (CDS) that will allow for measurement-based integrative care for the treatment of addiction and other mental disorders including depression and PTSD. The company's CDS combines comprehensive psychological and neurocognitive diagnostics, which allow for more informed treatment decisions; individualized treatment programs; and prediction of treatment success for each patient individually.